Tiragolumab

{
  "id": "MLC-T-ONC-008719",
  "term": "Tiragolumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance that binds to a protein called TIGIT, which is found on T cells and some other immune cells and helps keep the body’s immune response from being too strong. TIGIT may also keep T cells from killing cancer cells. Tiragolumab blocks TIGIT, which may help the immune system kill cancer cells. It is being studied in the treatment of some types of cancer. Tiragolumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor.",
    "A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses."
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tiragolumab/"
}